Filing Flows › Fate Therapeutics (FATE) › Q2 2026
Fate Therapeutics (FATE) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Fate Therapeutics (FATE) reported revenue of $2.1M for the second quarter 2026 (Q2 2026), +9% from a year earlier and +60% from the quarter before.
Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year), net loss $30.2M, operating cash flow −$23.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.1M | +60% | +9% |
| Operating profit | −$31.1M | — | — |
| Net earnings | −$30.2M | — | — |
| Operating cash flow | −$23.4M | — | — |
What changed
Revenue was $2.1M in Q2 2026, up 9% year over year and up 60% from the previous quarter.
Operating costs exceeded revenue by $31.1M, an operating margin of -1495.4%. Total costs fell 15% while revenue rose 9%. The quarter ended with a net loss of $30.2M, narrower than the previous quarter's $31.2M loss.
Operating cash flow was −$23.4M. Non-cash charges added back $2.8M of depreciation and amortization and $3.5M of share-based compensation. Capital expenditures of $80K exceeded it, leaving free cash flow of −$23.5M.
Questions
What was Fate Therapeutics' revenue in the second quarter 2026?
Fate Therapeutics (FATE) reported revenue of $2.1M for the second quarter 2026 (Q2 2026), +9% from a year earlier and +60% from the quarter before.
Source: Fate Therapeutics 10-Q on SEC EDGAR.